Merck KGaA has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligase-binding moiety covalently bonded to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting moiety through a linker reported to be useful for the treatment of cancer.
Les Laboratories Servier SAS and Vernalis (R&D) Ltd. have disclosed son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer, immunological and genetic disorders.
Foresight Therapeutics (Hefei) Co. Ltd. has described Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Hinova Pharmaceuticals Inc. has divulged glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes, obesity, hepatic steatosis and polycystic ovary syndrome.
Genescience Pharmaceuticals Co. Ltd. has identified camptothecin derivatives acting as DNA topoisomerase I inhibitors reported to be useful for the treatment of cancer.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) targeting moiety via a linker reported to be useful for the treatment of cancer.
Ensem Therapeutics Inc. has disclosed phosphatidylinositol 3-kinase α (PI3Kα) inhibitors, particularly PI3Kα mutant inhibitors, reported to be useful for the treatment of cancer.
Technische Universität München has described conjugates comprising a silicone-based fluoride acceptor (SiFA)-based peptide targeting moiety covalently linked to radiolabeled chelating agents through a divalent linker.
RSS